Vaxart Inc

Vaxart Inc(VXRT)股票分析

$0.320

-0.080 (-25.06%)收盘时

Loading chart…
最高
0.430
开盘
0.412
成交量加权均价
0.35
成交量
24.02M
市值
118.17M
最低
0.300
成交额
8.41M
企业价值/息税折旧摊销前利润(TTM)
-7.36

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.

估值指标

Vaxart Inc(VXRT)当前预期市盈率为 -1.49,5 年平均预期市盈率为 -2.67。

预期市盈率

合理
5 年均值 P/E
-2.67
当前P/E
-1.49
高估
-0.50
低估
-4.85

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-3.94
当前EV/EBITDA
-7.36
高估
5.18
低估
-13.05

预期市销率

合理
5 年均值 P/S
187.20
当前P/S
3.41
高估
620.85
低估
-246.46

Alphio AI 对 VXRT 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%VXRT

$1.66

情景价格

基

基准

基准 · 50%VXRT

$1.28

情景价格

悲

悲观

悲观 · 25%VXRT

$0.91

情景价格

事件时间线

2026-07-06 (ET)

16:30:00

Vaxart Announces Safety Data from COVID-19 Oral Vaccine Trial

2026-07-01 (ET)

16:30:00

Vaxart Resolves Proxy Contest, Seeks Independent Director

2026-06-25 (ET)

09:30:00

Vaxart Secures $29M Funding for Oral Vaccine Trial

2026-01-15 (ET)

08:20:00

Vaxart Publishes Phase 1 Trial Data Showing Vaccine Efficacy in Breastfeeding Women

2025-11-05 (ET)

16:03:09

Dynavax Secures Licensing Deal for Vaxart's Oral COVID-19 Vaccine Initiative

资讯

VXRT 常见问题 —— 由 Alphio AI 解答

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易